SARASOTA, Fla., Oct. 21, 2004 (PRIMEZONE) -- The following is an investment opinion issued by eLocity Inc.
Diabetic Treatment Centers of America, Inc. (OTCBB:DBTC), Aastrom Biosciences, Inc. (Nasdaq:ASTM) and ViroPharma Incorporated (Nasdaq:VPHM).
Diabetic Treatment Centers of America, Inc. (OTCBB:DBTC), a company dedicated providing diabetics with significantly improved health and a better quality of life, announced after the closing bell Wednesday the opening of its first clinic in Utah. The company said the clinic will be located in the Salt Lake City suburb of Murray, Utah.
Arden Oliphant, Diabetic Treatment Centers of America, Inc. CEO stated, "Our first clinic in Utah will be located in the Salt Lake City suburb of Murray. In addition to providing our patients world class therapies, the operating procedures and business development strategies executed in this clinic will be the model as we plan for additional clinics in other cities around the United States.
She added, "Diabetes sufferers in the greater Salt Lake City area will soon enjoy life again. Our treatments will slow, stop, and in some cases even reverse the damaging effects of this terrible disease."
Shares of DBTC closed Wednesday at $1.15 a share.
Other Biotechnology Stocks showing interesting activity on Wednesday were:
Aastrom Biosciences, Inc. (Nasdaq:ASTM)
Shares of Aastrom Biosciences, Inc., a regenerative medicine company developing proprietary adult stem cell-based products, traded on high volume of 7.6 million shares Wednesday, 13 times its daily average, to close up 16 cents at $1.24. On Monday the company announced that along with the Institut de Terapia Regenerativa Tissular (PinkSheets:ITRT), their clinical trial in Barcelona, Spain will be expanded based on initial results from the first phase of patient treatments.
ViroPharma Incorporated (Nasdaq:VPHM)
Shares of ViroPharma Incorporated closed 69 cents higher Wednesday to finish the trading session at $2.90, an increase of 31.22%, on strong volume of over 2.5 millions shares. The pharmaceutical company announced earlier in the week a deal, worth $116 million up front plus royalties, to buy all U.S. rights to make, market and sell Vancocin-brand products from drug maker Eli Lilly and Co. to treat inflammation of the mucus membrane of the intestine.
About eLocity Inc: eLocity owns and operates three financial websites for investors.
-- PennyPicks.com, http://www.pennypicks.com/. Featuring active message boards for the penny stock trader, rumors and more. -- StockGrid.com, http://www.stockgrid.com/. Visit this site for our daily top stock "GRID Makers". We rank stocks on volume, message board activity, sentiment and trend forecast. -- Bell2Bell.com, http://www.bell2bell.com/. Bell2Bell features news stories, rumors, the InvestBoard and more.
Sign up for FREE at any of the sites above.
The newsletter is provided by eLocity Inc., an electronic broadcaster and publisher of this newsletter, is here after referred to as "the company". The company received compensation for this newsletter service for Diabetic Treatment Centers of America, Inc. The compensation is forty thousand dollars from a non-affiliated third party, Reynolds Finance Inc. Because the company is receiving compensation for its services, there is an inherent conflict of interest in the company statements and opinions and such statements and opinions cannot be considered independent.
The company reserves the right to trade in securities mentioned herein, and may make purchases or sales in such securities featured within our newsletter reports. The information contained in this publication is for informational purposes only, and not to be construed as an offer to sell or solicitation of an offer to buy any security. The company makes no representation or warranty relating to the validity of the facts presented nor does the company represent or warrant that all material facts necessary to make an investment decision are presented above. All statements of opinions, if any, (Our Summary) are those of the company.
The company relies exclusively on information gathered on the Public Company, such as public filings, press releases and its web sites. Investors should use the information contained in this publication as a starting point for conducting additional research on the Public Company in order to allow the investor to form his or her own opinion regarding the Public Company. Factual statements contained in this publication are made as of the date stated and they are subject to change without notice. The company is not a registered investment adviser, broker or a dealer.
Investing in the Public Company that this newsletter is providing service for should be reviewed is speculative and a high-risk and may result in the loss of some or all of any investment made in the client. This release may contain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended.
The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements.